Mestinon 60

Pyridostigmine bromide, the active ingredient in Mestinon 60, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It treats myasthenia gravis by enhancing neuromuscular transmission and reducing muscle fatigue in affected patients.

GNH USA supplies Mestinon 60 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon 60, an anticholinesterase medication, is used primarily in disorders of neuromuscular transmission.

- Generalized myasthenia gravis: improves overall muscle strength and reduces fatigue. - Ocular myasthenia gravis: lessens ptosis and diplopia. - Myasthenic crisis (adjunct therapy): supports neuromuscular function while definitive treatments are initiated.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased bowel movements. - Abdominal cramps: discomfort in the abdomen. - Increased salivation: excess oral secretions. - Muscle cramps: involuntary tightening of muscles. - Sweating: heightened perspiration.

Serious or Rare Side Effects: - Cholinergic crisis: severe muscle weakness and respiratory compromise. - Bradycardia: markedly slow heart rate. - Bronchospasm: narrowing of airways causing breathing difficulty. - Seizures: uncontrolled electrical activity in the brain. - Allergic reactions: rash, angioedema, or anaphylaxis. - Severe hypotension: sudden drop in blood pressure.

Before initiating therapy, consider the following safety measures. - Renal impairment: dose may need adjustment in reduced kidney function. - Asthma or COPD: monitor respiratory status for bronchospasm. - Cardiac disease: observe for bradycardia or heart block. - Pregnancy: use only when potential benefit outweighs risk. - Drug interactions: review all concomitant medications. - Store at ambient temperature: keep in original packaging, protect from moisture.

Pyridostigmine bromide can interact with several medicines; awareness helps avoid adverse outcomes.

Major Interactions (Avoid): - Neostigmine: additive cholinergic effects may precipitate crisis. - Beta‑blockers: can exacerbate bradycardia. - Magnesium sulfate: potentiates neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: may diminish pyridostigmine efficacy. - Loop diuretics (e.g., furosemide): can increase pyridostigmine plasma levels. - Succinylcholine (anesthetic): additive neuromuscular effects require careful monitoring.